GlaxoSmithKline Pharmaceuticals Limited

BSE:GLAXO.BO

$2159.3 INR

-$84.8 (-3.78%)

Volume
8.87K
Average Volume
11.4K
Market Capitalization
$365.8B
P/E Ratio
56.47
Dividend Yield
1.48%
Price Target
$
Year High
$2649.95
Year Low
$1228.00
Payout Ratio
$0.00
Current Ratio
$1.71

Industry, Sector & symbol

Stock Exchange Bombay Stock Exchange
CEO Mr. Bhushan Akshikar
Industry Drug Manufacturers - General
Sector Healthcare
Current Symbol GLAXO.BO
CUSIP None
CIK None
Web https://india-pharma.gsk.com
Phone 91 22 2495 9595
Currency INR
Employees 3680
Country IN

Liquidity

Debt-to-Equity Ratio 0.01
Payout Ratio 0.00
Current Ratio 1.71
Quick Ratio 1.32
Cash Ratio 0.05

Sales & Book Value

Annual Sales $32.52B
Price / Sales 11.06
Cash Flow 38.24
Price / Cash Flow 56.47
Price / Book 23.76

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Strong Buy
Rating Score(0-5) 5
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $36.05
Trailing P/E Ratio 56.47
PEG Ratio 44.69
P/E Growth 44.69
Net Income $6.11B
Net Margin 19.58%
Pretax Margin 27.03%
Return on Equity 78.97%
Return on Assets 19.81%

Financials Score

AltmanZ Score 15.96
Piotroski Score 8.00
Working Capital 10.38B
Total Assets 32.7B
Ebit 8.49B
Market Cap 395.43B
Total Liabilities 17.31B

Poll Results

About GlaxoSmithKline Pharmaceuticals Limited (BSE:GLAXO.BO) Stock

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of Shingles and Post herpetic neuralgia. It a ... lso provides specialty medicines comprising NUCALA for severe eosinophilic asthma; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; TENOVATE and Flutivate for skin conditions to reduce inflammation; PHYSIOGEL for dry skin and dry skin associated with redness and itch; Zimig for fungal skin infections; COBADEX CZS, a multivitamin; and Supacef, a bactericidal cephalosporin antibiotic. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Frequently Asked Questions

What is the current GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO) stock price?

GlaxoSmithKline Pharmaceuticals Limited(BSE:GLAXO.BO) stock price is $2159.3 in the last trading session. During the trading session, GLAXO.BO stock reached the peak price of $2649.95 while $1228.0 was the lowest point it dropped to. The percentage change in GLAXO.BO stock occurred in the recent session was --3.78% while the dollar amount for the price change in GLAXO.BO stock was -$-84.8.

GLAXO.BO's industry and sector of operation?

The BSE listed GLAXO.BO is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of GLAXO.BO?

Dr. Rashmi Hegde M.D. | Executive Vice President of Medical
Ms. Simrat Sohal | Vice President of Ethics & Compliance
Mr. Juby Chandy | Whole-Time Director & Chief Financial Officer
Mr. Amit G. Pandey | Executive Vice President of Legal
Ms. Sukanya Choudhary | Executive Vice-President of Regulatory Affairs

How many employees does GLAXO.BO have?

Number of GLAXO.BO employees currently stands at 3680. GLAXO.BO operates from GSK House, Mumbai, None 400030, IN.

Link for GLAXO.BO official website?

Official Website of GLAXO.BO is: https://india-pharma.gsk.com

How do I contact GLAXO.BO?

GLAXO.BO could be contacted at phone #91 22 2495 9595 and can also be accessed through its website. GLAXO.BO operates from GSK House, Mumbai, None 400030, IN.

How many shares of GLAXO.BO are traded daily?

The average number of GLAXO.BO shares traded daily for last 3 months was 11.4K.

What is the market cap of GLAXO.BO currently?

The market value of GLAXO.BO currently stands at $365.8B with its latest stock price at $2159.3